Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adolescents 11-18 years of age~* virgins (both male and female) with no intention of becoming sexually active during the study period~* who have been properly vaccinated against diphtheria, tetanus, pertussis~Exclusion Criteria:~* who had a previous confirmed or suspected disease caused by N. meningitidis;~* who have previously been immunized with a meningococcal vaccine~* who have received prior human papillomavirus (HPV) vaccine;~* who have any serious acute, chronic or progressive disease~* who have epilepsy, any progressive neurological disease or history of Guillain-Barre syndrome;~* who have a known or suspected impairment/alteration of immune function, either congenital or acquired~* who are known to have a bleeding diathesis, or any condition that may be associated with a prolonged bleeding time;~* who have Down's syndrome or other known cytogenic disorders;

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- MenACWY + Tdap + HPV (Type: EXPERIMENTAL): Subjects received MenACWY concomitantly with Tdap and HPV at study month 0 followed by two injections of HPV at month 2 and 6
- MenACWY →Tdap → HPV (Type: EXPERIMENTAL): Subjects received MenACWY at study month 0 followed by one injection of Tdap at month 1, followed by three injections of HPV at months 2, 4, and 8
- Tdap →MenACWY → HPV (Type: EXPERIMENTAL): Subjects received Tdap at month 0 followed by one injection of MenACWY at month 1, followed by three injections of HPV at months 2, 4, and 8

Based on this trial design, predict the completion outcome and termination type (if applicable).